N/A
Manufactured by Galderma Laboratories, L.P.
42,441 FDA adverse event reports analyzed
Last updated: 2026-04-14
CALCITRIOL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Galderma Laboratories, L.P.. The most commonly reported adverse reactions for CALCITRIOL include NAUSEA, DIARRHOEA, CHRONIC KIDNEY DISEASE, OFF LABEL USE, VOMITING. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CALCITRIOL.
Out of 19,429 classified reports for CALCITRIOL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 42,441 FDA FAERS reports that mention CALCITRIOL. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include NAUSEA, DIARRHOEA, CHRONIC KIDNEY DISEASE, OFF LABEL USE, VOMITING, RENAL FAILURE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Galderma Laboratories, L.P. in connection with CALCITRIOL. Always verify the specific product and NDC with your pharmacist.